Savara Inc.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com

Website

http://www.savarapharma.com

External link for Savara Inc.

Industrie

Pharmaceutical Manufacturing

Größe des Unternehmens

11-50 Mitarbeiter

Hauptsitz

Vereinigte Staaten

Typ

Öffentliches Unternehmen

Gegründet

2007

Spezialitäten

biotech, biopharma, pulmonary, dry-powder, dpi, therapeutics, lung, respiratory, aerosol, inhaler, drug delivery, and rare disease